FORTE:
Get strong to fight childhood cancer: an excercise intervention for children and adolescents undergoing anti-cancer treatment
By pooling the leading expertise on a European and cross-Atlantic level, the FORTEe project aims to evaluate a personalised and standardised exercise intervention for children and adolescents undergoing anti-cancer treatment.
Weitere Informationen finden Sie hier
Projektpartnerin: Mirja Gotte (Kindheitsforschung)
Förderzeitraum: 01.03.2021 bis 31.08.2026
MAESTRIA:
Machine Learning Artificial Intelligence Early Detection Stroke Atrial Fibrillation
MAESTRIA will create multi-parametric digital tools based on a new generation of biomarkers that integrate artificial intelligence (AI) processing and big data from cutting edge imaging, electrocardiography and omics technologies. It will develop novel biomarkers, diagnostic tools and personalized therapies for atrial cardiomyopathy.
Weitere Informationen finden Sie hier.
Projektpartner: Prof. Dobormir Dobrev (Institut für Pharmakologie)
Förderzeitraum: 01.03.2021 bis 28.02.2026
RETENTION:
heaRt failurE paTient managEment and iNTerventIOns usiNg continuous patient monitoring outside hospitals and real world data:
RETENTION aims to develop and deliver an innovative platform supporting enhanced clinical monitoring and interventions aimed at improving the clinical management of patients with chronic HF, reducing their mortality and hospitalisation rates, and improving their quality of life, safety, and well-being.
Weitere Informationen finden Sie hier.
Projektpartner: Prof. Arjang Ruhparwar (Herzchirugie)
Förderzeitraum: 01.05.2021 bis 30.04.2025
4-IN THE LUNG RUN
Towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening
Using Computed Tomography as a preventive examination method to increase early detection of lung cancer.
Pressemitteilungen finden Sie hier.
Beteiligt: Prof. Clemens Aigner
Förderungszeitraum: 01.01.2020 bis 31.12.2024
NECTAR:
NEutron Capture-enhanced Treatment of neurotoxic Amyloid aggRegates
NECTAR proposes an alternative and revolutionary strategy to address AD (Alzheimer’s Disease) treatment, suggesting and investigating a therapy based mainly on nuclear physics principles and phenomena, i.e. neutron capture nuclear reactions and structural damage of AD Aβ aggregates induced by ionizing radiations (IRs)
Weitere Informationen finden Sie hier.
Projektpartner: Prof. Richard Dodel (Lehrstuhl der Geriatrie)
Förderzeitraum: 01.04.2021 bis 30.09.2024
HARMONIC
Health effects of cArdiac fluoRoscopy and MOderN radIotherapy in paediatriCs
HARMONIC will develop tools and allow definition of guidelines on optimization techniques to guide treatments
toward reduction of patient doses in paediatric cardiology and oncology.
Weitere Informationen finden Sie hier.
Konsortialführung: Instituto de Salud Global de Barcelona
Beteiligt: Prof. Dr. Timmermann und Prof. Dr. Brualla
Förderungszeitraum: 01.06.2019 bis 31.5.2024
AutoCRAT
Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis
AutoCRAT will develop novel sustainable cell and cell-derived therapies for osteoarthritis (OA). Osteoarthritis, a major disease, results in degradation of cartilage.
Pressemitteilungen finden Sie hier.
Konsortialführung: National University of Ireland
Beteiligt: PD Dr. Giebel (Transfusionsmedizin)
Förderungszeitraum: 01.01.2020- 31.12.2023
CLEVER Cities:
Cities Co-designing Locally tailored Ecological solutions for Value added, socially inclusive Regeneration in Cities:
CLEVER Cities applies a city centric approach, starting by key urban regeneration challenges and employing strong local partner clusters, to foster sustainable and socially inclusive urban regeneration locally, in Europe and globally.
Weitere Informationen finden Sie hier.
Folgen sie dem Twitter Account von CLEVER Cities hier.
Pressemitteilungen finden Sie hier.
Konsortialführung: Freie und Hansestadt Hamburg
Beteiligt: Prof. Dr. rer. nat. Moebus (Zentrum für urbane Epidemiologie)
Förderungszeitraum: 01.06.2018 bis 31.05.2023
Repo-Trial:
An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes:
"De novo drug design requires 10 to 15 years until market entry. We want to help patients faster and more efficiently. In comparison to de novo drug design, drug repurposing can happen much faster, costs less, and imposes a lower risk. The time for validation of a known drug’s potential new purpose is significantly reduced because less or no animal experiments are required, clinical studies can be conducted sooner and potential side effects are already known."
Weitere Informationen finden Sie hier.
Konsortialführung: Universität Maastricht
Beteiligt: Prof. Dr. Kleinschnitz (Klinik für Neurologie)
Förderungszeitraum: 01.02.2018 bis 01.02.2023
PREMESTEM
Brain injury in the premature born infant: stem cell regeneration research network
This project will provide new knowledge regarding the best regimen, timing, dose, and route of administration of human mesenchymal stem cells(H-MSC) for regenerating the brain damage in infants born preterm
Weitere Informationen finden Sie hier.
Beteiligt: Prof. Dr. Ivo Bendix, Prof. Felderhoff Müser
Förderungszeitraum: 01.01.2020 - 31.12.2022
EVPRO
EVPRO - Development of Extracellular Vesicles loaded hydrogel coatings with immunomodulatory activity for Promoted Regenerative Osseointegration of revision endoprosthesis
EVPRO will develop a novel bioinspired adaptive coating for hip revision endoprosthesis.
Weitere Informationen finden Sie hier.
Konsortialführung: Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Beteiligt: PD Dr. Giebel
Förderungszeitraum: 01.01.2019 bis 31.12.2022
BigMedilytics:
Big Data for Medical Analytics
BigMedilytics (Big Data for Medical Analytics) is the largest EU-funded initiative to transform the region’s healthcare sector by using state-of-the-art big data technologies to achieve breakthrough productivity in the sector by reducing cost, improving patient outcomes and delivering better access to healthcare facilities simultaneously.
Weitere Informationen finden Sie hier.
Konsortialführung: Philips Electronics Netherlands
Beteiligt: Dr. Becker (Klinik der Nephrologie)
Förderungszeitraum: 01.01.2018 bis 28.02.2022
JUSTSO
Analysis, Knowledge dissemination JUustice implementation and Special Testing of novel Synthetic Opioids
JUSTSO will develop new rapid and portable analytical methods of NSO present in biological specimens, to be later confirmed and extended by laboratory procedures.
Weitere Informationen finden Sie hier.
Konsortialführung: Universität Cagliari
Beteiligt: Prof. Dr. Moebus (Zentrums für urbane Epidemiologie)
Förderungszeitraum: 01.10.2018 bis 30.09.2020
Multimot:
Capture, dissemination and analysis of multiscale cell migration data for biological and clinical applications:
This proposal addresses the call topic 'Advancing bioinformatics to meet biomedical and clinical needs' with the focus on the standardization, dissemination and meta-analysis of cell migration data.
Weitere Informationen finden Sie hier.
Konsortialführung: VIB
Beteiligt: Prof. Dr. Gunzer (Experimentelle Immunologie)
Förderungszeitraum: 01.08.2015 bis 31.07.2018
